logo
The 5 Best Cereals to Reduce Stroke Risk, According to Cardiologists and Dietitians

The 5 Best Cereals to Reduce Stroke Risk, According to Cardiologists and Dietitians

Yahooa day ago
Reviewed by Dietitian Maria Laura Haddad-Garcia
Cardiovascular disease (CVD) and stroke are among the leading causes of death and disability in the United States. While genetics and lifestyle play a role, diet is a key player in stroke prevention—and your morning cereal can help tip the scales in your favor.
"A high-fiber, low-sodium diet can help to promote optimal blood sugar, blood pressure and cholesterol levels, which can reduce the risk of plaque formation, hypertension, diabetes and stroke," says Bhavna Suri, M.D, a cardiologist.
While breakfast cereals are a quick and easy choice, not all are made the same. Many are packed with added sugar and lack fiber—two strikes against stroke prevention. Instead, look for cereals that are low in added sugars and sodium, high in fiber and made with whole grains.
Here are five of the best cereals, approved by heart-health experts, that can reduce your risk of stroke. Plus: tips on building a stroke-smart breakfast.
1. Shredded Wheat (Unfrosted)
When it comes to heart-healthy cereals, Post Shredded Wheat Original Spoon Size® cereal stands out. "When looking for a cereal to reduce your stroke risks, generally, you are looking for one that is high in fiber and low in added sugar," says Abigail Nessle, M.H.Sc., RDN, LDN. This option checks those boxes, with one serving (1 ⅓ cup) providing 8 grams of fiber, which is 28% of the Daily Value.
It also contains essential nutrients, including iron, niacin, phosphorus, magnesium and zinc. Magnesium, in particular, has been shown to protect against stroke risk (particularly in women), though more research is needed.
Plus, Post Shredded Wheat is sodium-free—a big win for a heart-healthy diet. Most Americans consume significantly more sodium than the recommended daily intake of 2,300 mg per day, with average intake exceeding 3,000 mg. Reducing sodium intake can help lower your blood pressure and reduce your risk of cardiovascular disease and stroke.
2. Cascadian Farm Organic No Added Sugar Cereals
Added sugars are a sneaky contributor to cardiovascular disease and stroke risk. Breakfast cereals are a common source of added sugar, even in those labeled as healthy due to their high fiber or whole grain content. Cascadian Farm Organic No Added Sugar offers a tasty solution. It comes in two flavors—Vanilla Crisp and Mixed Berry—so you have a choice to fit your preferences.
Each 1 ¼-cup serving offers 5 g of protein and 5-6 (depending on the flavor) g of fiber—two nutrients that contribute to increased feelings of satiety. Plus: "One of the many superpowers of fiber is to help block the absorption of cholesterol that can turn into plaque in the veins and arteries," says Nessle. When cholesterol is elevated, blood flow can be blocked, resulting in a type of stroke called an ischemic stroke.
One caveat: Both flavors are higher in sodium than what many dietitians recommend for a stroke-smart breakfast, with 390-400 mg per serving. Karen E. Todd, RD, CSCS, EP-C, CISSN, suggests choosing a cereal with less than 140 mg of sodium per serving. Modifying the portion size or reducing sodium in other meals can help keep your total daily intake within recommended limits.
3. Post Grape-Nuts The Original
Upping your daily fiber is easy if you choose Post Grape-Nuts The Original as your morning cereal. Just one 1 ½-cup serving offers 7 g of fiber and zero added sugar, along with iron, folate, vitamin B6, niacin, thiamin, zinc and phosphorus.
Some research suggests that folic acid supplementation may lower stroke risk, though supplements can have varied effects depending on individual health conditions. That's why food sources like Grape-Nuts are ideal for getting these nutrients.
4. Old-Fashioned Rolled Oats
A classic for a reason, oats are a heart-healthy, high-fiber choice that makes a great addition to a stroke-smart breakfast. "Packed with 4-5 grams of fiber per ½ cup, [oats] lower cholesterol with beta-glucans and keep blood sugar steady,' says Todd. Beta-glucan, a component of soluble fiber found in oats, is especially beneficial for reducing cholesterol in the blood. Optimal dietary fiber intake also helps support a healthy weight, thereby reducing the risk of certain chronic diseases, such as cardiovascular disease.
For added fiber and antioxidants, stir in chia seeds or top with fresh berries.
5. Bran Cereals
Bran cereals are another fiber-rich pick, typically offering 5 to 7 g of fiber per serving. Many are also fortified with key vitamins and minerals, such as iron and vitamin D. Bran cereal may help manage blood pressure, cholesterol, and blood sugar—all critical factors in reducing the risk of cardiovascular disease. Just be sure to check the Nutrition Facts label—some brands sneak in more than 200 mg of sodium per serving.
How to Build a Stroke-Smart Breakfast
Building a stroke-smart breakfast means paying close attention to a few key nutrients. When choosing a morning cereal, Todd recommends avoiding those that are high in added sugar or sodium, as well as refined-grain cereals and instant oatmeal packets with added sugars. Here's how to round out your morning meal for better heart health:
Add Fruits or Vegetables
Potassium-rich foods, such as fruits and veggies, support heart health and are often missing from breakfast. "A 2023 review of more than 25 studies found that a diet rich in fruits and vegetables earlier in life may lower stroke risk compared with meat and fat intake," says Brittany Brown, RD, IBCLC, CDE.
Try blending leafy greens like spinach into a smoothie or topping your bowl of cereal with fresh berries.
Limit Sodium
Some common breakfast choices—like breakfast meats, biscuits and some processed cereals—are high in sodium. "Diets high in salt can increase your blood pressure and risk of stroke," says Suri. Aim to stay under 2,300 mg of sodium daily (ideally closer to 1,500 mg) for heart protection.
Cut Back on Added Sugar
While added sugar is found in obvious foods like pastries, tarts and muffins, it often sneaks into less obvious ones as well. Be sure to check the nutrition facts label when looking for a breakfast option. And limiting sugar doesn't mean that you can't satisfy your sweet tooth; Todd recommends turning to naturally sweet foods like fruit and unsweetened dairy products.
Incorporate Healthy Fats
"Some cereals contain nuts and flax seeds, which can improve our levels of good HDL cholesterol," says Suri. Add in walnuts, almonds, chia or hemp seeds for more heart health benefits.
Our Expert Take
"Your plate is a powerful tool for stroke prevention," says Todd. And if you're choosing cereal, then your bowl is too. A breakfast cereal made from whole grains, with minimal sugar and sodium, can become a daily opportunity to protect your health—starting with your heart.
Don't forget to boost your bowl with extras like fruit, seeds and nuts to enhance the fiber and nutrient profile.
Read the original article on EATINGWELL
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Unlocking Oncology's Future: 3 Trending Cancer Biotech Stocks with ‘Strong Buy' Ratings
Unlocking Oncology's Future: 3 Trending Cancer Biotech Stocks with ‘Strong Buy' Ratings

Yahoo

time15 minutes ago

  • Yahoo

Unlocking Oncology's Future: 3 Trending Cancer Biotech Stocks with ‘Strong Buy' Ratings

Cancer remains one of the most relentless challenges in modern medicine. In 2025, over 2 million new cancer cases are expected to be diagnosed in the United States. More than 618,000 people will die from the disease, which is equivalent to about 1,700 deaths each day. The scale of this health crisis is driving substantial investments and innovation in cancer research and treatment. As a result, the global oncology market is projected to reach $208.9 billion in revenue by 2025, with forecasts suggesting it could surpass $900 billion by 2034. This growth is fueled by increased cancer incidence, advances in precision and immunotherapy drugs, and billions of dollars in new partnerships and funding, such as Bristol-Myers Squibb's (BMY) recent $11 billion stake in next-generation cancer therapies. More News from Barchart Warren Buffett Warns Inflation Turns Business Into 'The Upside-Down World of Alice in Wonderland' But Weeds Out 'Bad Businesses' Why GOOGL Stock May Be the Market's Next Big Winner Alphabet Posts Lower Free Cash Flow and FCF Margins - Is GOOGL Stock Overvalued? Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. High-potential cancer specialists like Elicio Therapeutics (ELTX), Cellectis (CLLS), and Autolus Therapeutics (AUTL) are earning coveted 'Strong Buy' analyst ratings. Despite this recognition, each remains well below large-cap valuations, which leaves ample room for sharp upside if upcoming clinical and regulatory catalysts play out in their favor. Could one of these under-the-radar biotech firms deliver the next big breakthrough in cancer treatment — and major upside for investors? Let's dive into these three cancer biotech stocks now. Elicio Therapeutics Elicio Therapeutics (ELTX) is a clinical-stage biotech pioneering immunotherapies for solid tumors, with a market capitalization of $158 million. ELTX has posted a YTD gain of 92.7%, and is up 102.6% over the past 52 weeks. Its price-book ratio stands at an elevated 17.6x, well above the sector median of 2.47x. Elicio's lead asset, ELI-002 7P, is advancing through the pivotal Phase 2 AMPLIFY-7P trial targeting pancreatic ductal adenocarcinoma (PDAC), with a critical interim analysis focused on disease-free survival slated for Q3 2025. This interim analysis is a key milestone for the company, particularly for its potential impact on PDAC. Ahead of this readout, H.C. Wainwright analyst Robert Burns reiterated a 'Buy' rating on shares and maintained his $13 price target. Elicio reported Q1 2025 R&D expenses of $7.8 million, a slight increase from $7.6 million in Q1 2024, tied primarily to the ongoing Phase 2 AMPLIFY-7P trial. General and administrative expenses grew to $3 million, up from $2.7 million due to higher personnel costs. The Q1 2025 net loss narrowed to $11.2 million, compared to $11.8 million in the same quarter last year, with a net loss per share improving to $0.87 from $1.15. Notably, ELTX augmented its financial position in Q2 by securing a $10 million senior secured note, extending its operational runway into early 2026 and granting the company flexibility for near-term initiatives. Analyst sentiment skews highly bullish as the two surveyed analysts assign ELTX a 'Strong Buy' rating, with an average price target of $12.50. This places the upside potential at approximately 26% from current levels. Cellectis Cellectis (CLLS) is a clinical-stage biotech company specializing in gene-edited cell therapies with a market capitalization of approximately $140 million. The stock has gained 60% in the year to date, and shares are up 25.2% in the past 52 weeks. Cellectis has a price-sales ratio of 2.26x, below the sector median of 3.6x, and a price-book ratio of 0.96x, significantly under the sector median of 2.47x, suggesting potential undervaluation relative to its peers. CLLS reported solid results for Q1 2025, with consolidated revenues and other income rising to $12 million from $6.5 million a year prior. This increase mainly stems from $5.9 million recognized under the AstraZeneca Joint Research Collaboration Agreement (AZ JRCA). Its cash reserves stood at $246 million as of March 31, 2025, projected to sustain operations well into the second half of 2027, providing ample runway for ongoing development. Research and development expenses slightly decreased to $21.9 million compared to the previous year, reflecting efficient management despite continued investment in pipeline advancement and manufacturing capabilities in Paris and Raleigh. Strategically, Cellectis' partnership with AstraZeneca is a cornerstone of its growth story. AstraZeneca's $140 million investment enhances Cellectis' financial footing and grants AstraZeneca exclusive rights to 25 genetic targets, with options to develop up to 10 candidate products. So far this collaboration is advancing two CAR-T programs aimed at hematological malignancies and solid tumors. Analyst sentiment is unanimously bullish, with the five surveyed analysts assigning Cellectis a consensus 'Strong Buy' rating. The average price target of $5.60 implies compelling upside of approximately 91% from the current share price. Autolus Therapeutics Autolus Therapeutics (AUTL) develops advanced autologous CAR-T cell therapies for blood cancers, with a market capitalization of $670 million. The stock is up 8.7% year-to-date, but down 45% over the past 52 weeks. Its price-sales ratio of 69.4xx is markedly above the sector's 3.54x median, while its 1.89x price-book ratio remains below group averages of 2.47x. In Q1 2025, Autolus reported $9 million in net product revenue, driven largely by the commercial rollout of AUCATZYL (Obe-cel), its lead CAR-T therapy, across 39 fully activated U.S. centers. Patient access continues to grow, capturing coverage for roughly 90% of U.S. medical lives as payer uptake accelerates. Costs of sales totaled $18 million, including delivered but as-yet-unrecognized product tied to deferred revenue and royalty obligations, a natural part of early stage commercial launches. Research and development expenses dropped to $26.7 million from $30.7 million year-over-year, with much of that shift driven by the transition of manufacturing expenses to sales costs. Loss from operations widened to $65.2 million due to launch investments, and net loss reached $70.2 million or $0.26 per share. On the regulatory front, Autolus scored a critical win in July as AUCATZYL secured European approval for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. This unlocks a larger addressable market and enhances the company's global competitive position in engineered cell therapies. The analyst outlook remains unequivocally positive as the nine surveyed analysts rate AUTL a consensus 'Strong Buy,' with a mean target of $9.84, implying 285% upside potential from current levels. Conclusion With major catalysts ahead and strong analyst backing, the odds favor upward momentum as data readouts and commercial expansion play out. Given their positioning and partnerships, these three stocks could deliver outsized gains in the coming quarters, especially if results come in strong. On the date of publication, Ebube Jones did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on

Deion Sanders says he had bladder cancer but will coach Colorado Buffaloes this season
Deion Sanders says he had bladder cancer but will coach Colorado Buffaloes this season

Yahoo

time15 minutes ago

  • Yahoo

Deion Sanders says he had bladder cancer but will coach Colorado Buffaloes this season

BOULDER, Colo. (AP) — Colorado coach Deion Sanders disclosed Monday that he was diagnosed with an aggressive form of bladder cancer but after surgery his oncologist considered him cured. Dr. Janet Kukreja, the director of urologic oncology at the CU Cancer Center/UCHealth University of Colorado hospital, said Sanders had his bladder removed as part of the surgical plan. Sanders plans to oversee the Buffaloes this season as he enters his third season at Colorado. Sanders, who turns 58 next month, spoke to the media on the eve of fall camp. He brought his medical team with him to discuss his diagnosis. The charismatic coach returned to campus last week and announced on social media, 'Back and Feeling Great!' He's missed football camps in Boulder this summer amid reports that he's been ill. ___ AP college football: and

Colorado coach Deion Sanders had bladder removed after bladder cancer diagnosis
Colorado coach Deion Sanders had bladder removed after bladder cancer diagnosis

Yahoo

time15 minutes ago

  • Yahoo

Colorado coach Deion Sanders had bladder removed after bladder cancer diagnosis

Colorado coach Deion Sanders announced Monday that he had been diagnosed with bladder cancer. Sanders held a news conference to reveal the news as Colorado embarks on fall camp ahead of the 2025 season. Dr. Janet Kukreja, Sanders' doctor, said that Sanders had his bladder removed after a malignant tumor was found and that he had been "cured" from the cancer. The Pro Football Hall of Famer had been away from the team and at his home in Texas after spring practice to deal with health issues. He appeared at Big 12 media days earlier in July and declined to answer questions about his health while at the podium during his appearance there.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store